Cigna (CI)
Health Care · Managed Health Care · NYSE
A diversified global health services organization providing integrated pharmacy benefits and comprehensive health insurance solutions.
What Cigna does
The Cigna Group is a global health company that provides insurance and health services. Its operations include pharmacy benefit management, specialty pharmacy services, and a wide array of health insurance products, including medical, dental, behavioral health, and supplemental benefits.
Themes: pharmacy benefit management (PBM), managed care, health services, specialty pharmacy
Fundamentals
- Price$281.03 as of 2026-10-08 close
- Market cap$74.3B as of 2026-07-24 (share count; price 2026-10-08)
- 1-year return-8.4% 2025-10-08 close $306.76 → 2026-10-08 close $281.03
- P/E11.65 as of 2026-10-08
- Net margin+2.2% FY2025, SEC XBRL
- ROE+14.2% FY2025, SEC XBRL
- Debt / equity0.75 as of 2026-09-03
- Revenue growth (YoY)+7.8% as of 2026-09-03
- Revenue CAGR (3y)+15.0% SEC XBRL
- Beta0.12 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +2.3%; at least 9 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How CI compares in its sector
- price-to-earnings ratiobottom 25% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 72 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CI is not currently in any published Top 10 list. Its scores are below.
Top 10 score
58.6 #280 of 1,379 scored · #35 of 151 in Health Care
Valuation 85th (price to earnings 11.6, price to book 1.7) and capital return 84th (net share count bought back over the year 5.2, consecutive years of dividend increases 9 years); weakest is profitability (42nd, operating margin 3.3%, return on equity 14.2%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, CI's dividend was covered by reported results (earnings payout 7%, operating-cash-flow payout 4%). This describes past coverage, not a forecast.
- Earnings payout7% dividends / net income
- Operating-cash-flow payout4% dividends / operating cash flow — capital spending was not reported, so this does not subtract it
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Cigna looks technically
Cigna (CI) is trading 0.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 6 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 0.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +0.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $277.51 | $277.51 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $279.68 | $279.68 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 6 trading days ago — a "death cross", a bearish long-term signal | 6 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 0.5% above | +0.5% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 12.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30) | 56.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($262.85 to $283.13) — its "stochastic" reading is 90 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 89.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $315.47 | $315.47 |
|---|---|---|
| From the 52-week high | it is 10.9% below its 52-week high (its highest price of the past year) | -10.9% |
| Above the 52-week low | it is 17.3% above its 52-week low (its lowest price of the past year) | +17.3% |
| Below the 52-week high | it is 10.9% below its highest point of the past year | 10.9% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $370.82 (set on 2024-09-16) | $370.82 |
| Given back of the 52-week move | over the past year its closes ranged ($244.41 to $311.00), and it has recovered around half of its fall from last year’s high — 55% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $285.56 to $287.69. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. Worth noting that the whole move happened in 28 days, so it is a narrow thing to be measuring a retracement against. | 55.0% |
| From the all-time high | it is 24.2% below its all-time high | -24.2% |
| Nearest price level | it is sitting right on a support level at $279.66 — a price it turned at 7 times since 2025-09-25, most recently on 2026-07-16. Since 2024-10-08 it has 4 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $8.00 (set on 2008-11-21) | $8.00 |
| Above the all-time low | it is 3412.9% above its all-time low | +3,413% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 47th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $7.28 between its high and its low — about 2.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $7.28 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $262.92 and $287.89 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $262.92 – $275.40 – $287.89 |
| Typical daily range (% of price) | its price moves about 2.6% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.6% |
| Stretch from the 200-day average | it is trading 0.2 daily ranges above its 200-day average price (0.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.91× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.1% since the prior reading | +0.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 3.5% below the previous close 49 sessions ago and has not traded back through the level it left behind at 296.47 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.5% |
| Gap filled | a 2.1% gap down opened on 2026-08-05 has been "filled" 44 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 44 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 5 sessions in a row, a +4.88% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 5 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.8 percentage points (the stock gained 1.9% while the market gained 1.0%) | +0.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 6.8 percentage points (the stock lost 3.0% while the market gained 3.8%) | -6.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 15.5 percentage points (the stock gained 1.9% while the market gained 17.5%) | -15.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 23.4 percentage points (the stock lost 8.4% while the market gained 15.0%) | -23.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.8% of the share price, which is taken to mean a barrier that gives way easily. | -0.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $279.37 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +0.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $276.93 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | +1.5% |
Double bottom, bullish — forming · entry $290.05 · 45 sessions in
Price levels it has turned at before
CI last closed at $281.03 on 2026-10-08. Since 2024-10-08 it has turned at 4 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $279.66 | Support | 0.5% below the last close | turned there 7 times · 2025-09-25 to 2026-07-16 |
| $289.60 | Resistance | 3.0% above the last close | turned there 8 times · 2025-10-16 to 2026-09-14 |
| $271.64 | Support | 3.3% below the last close | turned there 11 times · 2025-01-30 to 2026-09-09 |
| $297.07 | Resistance | 5.7% above the last close | turned there five times · 2025-05-15 to 2026-06-12 |
| $264.36 | Support | 5.9% below the last close | turned there six times · 2024-12-17 to 2026-10-01 |
| $307.32 | Resistance | 9.4% above the last close | turned there 13 times · 2024-11-01 to 2026-07-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Recent death cross (50-day crossed below 200-day) · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.75 mean, 1=Strong Buy…5=Strong Sell) — 24 analysts
- Mean price target$342.29 range $288.00 – $400.00; median $345.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CI
- Consensus EPS estimate$7.51 next reporting period, as of 2026-10-07
- Estimate change, 30 days+$0.01225 (+0.2%) from $7.49, on 2026-09-02, 35-day window
- Readings revised upward33% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Exposure to evolving and complex government regulations in health care and pharmacy benefits.","Risk of adverse changes in medical costs or pharmacy benefit obligations.","Significant dependence on pharmacy and health service contracts and government programs."]
What changed in the latest 10-Q
AI-assisted comparison of CI's 10-Q filed 2026-07-30 against the prior one filed 2026-04-30.
Management's Discussion & Analysis (MD&A)
- Reworded:
- The newer filing (filed 2026-07-30) states the MD&A evaluates financial condition 'as of June 30, 2026' and results of operations 'for the three and six months ended June 30, 2026'; the older filing (filed 2026-04-30) stated 'as of March 31, 2026' and 'for the three months ended March 31, 2026'.
- The newer filing (filed 2026-07-30) ends the forward-looking statements risk list with 'our ability to develop and maintain satisfactory relationships with health care payors, physic...' (text appears truncated at same point as older filing); the older filing (filed 2026-04-30) ends with '...health care payors, physicians, h' (also truncated, with slight difference in truncation point).
- Notes:
- Only the provided excerpts were compared. Both texts appear truncated at the end of the forward-looking statements risk factor list, so changes after that point could not be assessed.
- Page-break artifacts (e.g., page numbers 27, 28, 30, 31) appear in both texts and were not treated as substantive changes.
Risk Factors
- Added:
- In the newer filing (filed 2026-07-30), the share repurchase activity table is updated to cover the quarter ended June 30, 2026, with new monthly periods (April 1-30, May 1-31, June 1-30, 2026) and new figures: 663 shares at $268.55 in April, 864,782 shares at $289.18 in May, 10,003 shares at $286.56 in June, totaling 875,448 shares at an average price of $289.13; 864,544 shares purchased as part of the publicly announced program; and approximately $6,480 million remaining that may yet be purchased (May and June rows).
- In the newer filing (filed 2026-07-30), footnote (1) states employees tendered 663 shares in April, 238 shares in May and 10,003 shares in June 2026.
- In the newer filing (filed 2026-07-30), under Rule 10b5-1 Plan Elections, a May 4, 2026 plan by Nicole Jones (Executive Vice President, Chief Administrative Officer and Chief Human Resources Officer) is disclosed, covering the sale or exercise of: up to 9,051 shares of common stock; shares issuable upon vesting of performance awards based on 5,313 shares at target (0% to 200% range); and up to 15,346 vested stock options plus associated sale of shares to cover exercise price, tax obligations, fees and 50% of resulting net shares, through May 4, 2027.
- In the newer filing (filed 2026-07-30), under Rule 10b5-1 Plan Elections, a June 2, 2026 plan by Everett Neville (Executive Vice President and Special Advisor to the Chief Executive Officer) is disclosed, covering the sale of up to 1,234 shares of common stock through March 2, 2027.
- In the newer filing (filed 2026-07-30), the exhibit index omits exhibits 10.1 through 10.7 that appeared in the older filing.
- In the newer filing (filed 2026-07-30), the exhibit 101 description references the period ended June 30, 2026.
- Removed:
- In the older filing (filed 2026-04-30), the share repurchase activity table covers the quarter ended March 31, 2026, with monthly periods January 1-31, February 1-28, and March 1-31, 2026: 621 shares at $271.97, 247,549 shares at $287.54, 20,230 shares at $276.51, totaling 268,400 shares at an average price of $286.67, zero shares purchased as part of the publicly announced program, and approximately $6,730 million remaining in each month.
- In the older filing (filed 2026-04-30), footnote (1) states employees tendered 621 shares in January, 247,549 shares in February and 20,230 shares in March 2026.
- In the older filing (filed 2026-04-30), under Rule 10b5-1 Plan Elections, a February 6, 2026 plan by David Cordani (Chair and Chief Executive Officer) is disclosed, covering the sale of shares upon vesting of performance awards based on 62,366 shares at target (0% to 200% range) and exercise of up to 212,543 vested stock options plus associated sale to cover exercise price, taxes, fees and 50% of net shares, through April 30, 2027.
- In the older filing (filed 2026-04-30), the exhibit index includes exhibits 10.1 (Offer Letter for David Cordani dated February 25, 2026), 10.2 (Offer Letter for Brian Evanko dated February 25, 2026), 10.3, 10.4, 10.5, 10.6, and 10.7 (forms related to the Cigna LTIP), which are absent from the newer filing.
- In the older filing (filed 2026-04-30), the exhibit 101 description references the period ended March 31, 2026.
- Reworded:
- In the newer filing (filed 2026-07-30), the Share Repurchase Program column total for shares purchased as part of the publicly announced program changed from 0 (in the older filing) to 864,544.
- In the newer filing (filed 2026-07-30), the introductory sentence to Rule 10b5-1 Plan Elections changed from "the following 10b5-1 director and officer trading plan arrangement change occurred" to "the following 10b5-1 director and officer trading plan arrangement changes occurred", and the closing paragraph changed from "This trading plan was entered into" to "These trading plans were entered into".
- Notes:
- The provided source texts are labeled as the Risk Factors section but actually contain Item 1A plus other items (Item 2, Item 5, Item 6, and signature). The comparison covers all the text that was supplied in both sources.
- No actual changes to the risk factor text itself (Item 1A) were identified; Item 1A wording is identical in both filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 3 sells ($6M) — 2 selling insiders
- Last 180 days · read to 2026-10-040 buys · 17 sells ($66M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-03. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 26 matched disclosures for CI from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding CI as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 46,225,772
- Reported value $12,743,520,773
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CI's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CI had 6,562,998 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CI had 2.48% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.6 days to cover at the same settlement.
- Reported short interest (shares) 6,562,998
- Short interest (% of shares outstanding) 2.48%
- Prior settlement (shares) 6,274,787
- Reported change 4.59%
- Days to cover (reported) 4.6
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CI vs…
Cigna is found in…
Frequently asked questions
What does Cigna (CI) do?
The Cigna Group is a global health company that provides insurance and health services. Its operations include pharmacy benefit management, specialty pharmacy services, and a wide array of health insurance products, including medical, dental, behavioral health, and supplemental benefits.
What sector is Cigna (CI) in?
Cigna (CI) is classified in the Health Care sector. Its industry is Managed Health Care. It trades on NYSE.
Does CI pay a dividend?
Yes — Cigna (CI) pays a dividend, with an indicated yield of about 2.27% and at least 9 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Cigna's (CI) competitors?
Notable peers of Cigna (CI) include UnitedHealth Group, CVS Health, Elevance Health, Humana and Centene. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in CI?
Yes — we hold 26 matched STOCK Act disclosures for CI from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Cigna (CI) overbought or oversold right now?
Cigna (CI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 56, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CI come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.